MSD Completes Acquisition of Investigational B-Cell Depletion …
WEB3 days ago · As a matter of policy, MSD provides updates to its financial outlook once each quarter and will provide an update to its full-year financial outlook when it reports third-quarter 2024 results on October 31. About CN201 CN201 is a novel CD3xCD19-targeting T-cell-engager bispecific antibody, designed to target B cells for elimination by T cells.
What can we help you find? - Merck
WEB3 days ago · Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage ...
Merck Completes Acquisition of Investigational B-Cell Depletion …
WEBMerck, known as MSD outside of the United States and Canada, announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage bispecific antibody for the treatment …
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, …
WEBAug 9, 2024 · CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Merck Completes Acquisition of Investigational B-Cell Depletion …
WEB3 days ago · Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Mercks pipeline RAHWAY,...
Merck Completes Acquisition of Investigational B-Cell ... - BioSpace
WEB3 days ago · Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline RAHWAY, N.J.-- (BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel ...
Merck to Acquire CN201 from Curon Biopharmaceutical
WEBSep 11, 2024 · Merck, known as MSD outside the US and Canada, has announced a definitive agreement to acquire CN201, a promising bispecific antibody developed by Curon Biopharmaceutical. This transaction, valued at $700 million upfront, includes potential milestone payments up to $600 million.
Merck: acquisition of therapeutic antibody CN201 finalized
WEB3 days ago · Merck announced on Tuesday that it had completed the acquisition of the proprietary bispecific antibody CN201 from Curon Biopharmaceutical in order to strengthen its expertise in the treatment of...
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, …
WEBAug 9, 2024 · Merck plans to evaluate CN201 as a treatment for B-cell malignancies as well as investigate its potential to provide a novel, scalable option for the treatment of autoimmune diseases.
Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific …
WEBMay 29, 2024 · CN201 is a novel CD19-targeting T-cell-engaging IgG4 bispecific antibody. This phase I study is to investigate the safety, tolerability and preliminary efficacy of CN201 in B-ALL (ClinicalTrials.gov identifier: NCT05579132).
- Some results have been removed